SlideShare a Scribd company logo
Reimbursement were prices are negotiated based on value for the country as a whole, by using existing health technology assessment :  Case Study using Blood Glucose Test Strips Chris Cameron,  Health Economist, Canadian Agency for Drugs and Technologies in Health  CHSRF iHEA Pre-Conference Symposium, July 11, 2011
Health Technology Assessment (HTA) ,[object Object],[object Object],[object Object]
Option: pan-Canadian HTA-based price negotiation ,[object Object],[object Object],[object Object],[object Object],[object Object]
Example – Blood Glucose Test Strips ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Example – Blood Glucose Test Strips (c) VBP of test strips at cost-effectiveness threshold of marginal sub-group  (a) (b) Current pricing of test strips in Canada (dashed line) a) Diminishing marginal utility of SMBG HTA-based price reduction from $0.76 to $0.30 using would save drug plans >$150 million annually and not compromise the health of Canadians
Be nefits – pan-Canadian HTA-based price Negotiation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Challenges – pan-Canadian HTA-based Price Negotiation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusion   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES
OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIESOPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES
OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES
Office of Health Economics
 
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationChallenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and Innovation
Canadian Cancer Survivor Network
 
Structured decision making approaches to the inclusion of multiple criteria i...
Structured decision making approaches to the inclusion of multiple criteria i...Structured decision making approaches to the inclusion of multiple criteria i...
Structured decision making approaches to the inclusion of multiple criteria i...
Office of Health Economics
 
Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...
Office of Health Economics
 
Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...
Office of Health Economics
 
CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?
Canadian Cancer Survivor Network
 
Are Wider Societal Effects Considered in Healthcare Decision-making? An over...
 Are Wider Societal Effects Considered in Healthcare Decision-making? An over... Are Wider Societal Effects Considered in Healthcare Decision-making? An over...
Are Wider Societal Effects Considered in Healthcare Decision-making? An over...
Office of Health Economics
 
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways ForwardUsing MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Office of Health Economics
 
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
Office of Health Economics
 
Pharma funding of patient groups: the building blocks of ethical and appropri...
Pharma funding of patient groups: the building blocks of ethical and appropri...Pharma funding of patient groups: the building blocks of ethical and appropri...
Pharma funding of patient groups: the building blocks of ethical and appropri...
Canadian Cancer Survivor Network
 
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
 
ISPOR poster ri lwcp 140515
ISPOR poster   ri lwcp  140515ISPOR poster   ri lwcp  140515
ISPOR poster ri lwcp 140515
Office of Health Economics
 
How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?
Canadian Cancer Survivor Network
 
The Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in CanadaThe Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in Canada
Canadian Cancer Survivor Network
 
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Office of Health Economics
 
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
 
Devlin mcda philadelphia ispor 150515
Devlin  mcda philadelphia ispor 150515 Devlin  mcda philadelphia ispor 150515
Devlin mcda philadelphia ispor 150515
Office of Health Economics
 
Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability
Office of Health Economics
 
Deborah Gersh, Data in Value- Based Health Care
Deborah Gersh, Data in Value- Based Health CareDeborah Gersh, Data in Value- Based Health Care
Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...
Office of Health Economics
 

What's hot (20)

OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES
OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIESOPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES
OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES
 
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationChallenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and Innovation
 
Structured decision making approaches to the inclusion of multiple criteria i...
Structured decision making approaches to the inclusion of multiple criteria i...Structured decision making approaches to the inclusion of multiple criteria i...
Structured decision making approaches to the inclusion of multiple criteria i...
 
Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...Data Governance for Real-World Evidence: Cross-country differences and recomm...
Data Governance for Real-World Evidence: Cross-country differences and recomm...
 
Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...
 
CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?
 
Are Wider Societal Effects Considered in Healthcare Decision-making? An over...
 Are Wider Societal Effects Considered in Healthcare Decision-making? An over... Are Wider Societal Effects Considered in Healthcare Decision-making? An over...
Are Wider Societal Effects Considered in Healthcare Decision-making? An over...
 
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways ForwardUsing MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
 
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
 
Pharma funding of patient groups: the building blocks of ethical and appropri...
Pharma funding of patient groups: the building blocks of ethical and appropri...Pharma funding of patient groups: the building blocks of ethical and appropri...
Pharma funding of patient groups: the building blocks of ethical and appropri...
 
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
 
ISPOR poster ri lwcp 140515
ISPOR poster   ri lwcp  140515ISPOR poster   ri lwcp  140515
ISPOR poster ri lwcp 140515
 
How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?
 
The Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in CanadaThe Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in Canada
 
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
 
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?Ira Klein, Can Value-based Contracting Work for Pharma Companies?
Ira Klein, Can Value-based Contracting Work for Pharma Companies?
 
Devlin mcda philadelphia ispor 150515
Devlin  mcda philadelphia ispor 150515 Devlin  mcda philadelphia ispor 150515
Devlin mcda philadelphia ispor 150515
 
Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability
 
Deborah Gersh, Data in Value- Based Health Care
Deborah Gersh, Data in Value- Based Health CareDeborah Gersh, Data in Value- Based Health Care
Deborah Gersh, Data in Value- Based Health Care
 
Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...
 

Similar to WHAT IF: The entry of new pharmaceuticals was managed and their prices were negotiated based on value for the country as a whole, by using existing health technology assessment capacity?

What can we learn from other countries?
What can we learn from other countries?What can we learn from other countries?
What can we learn from other countries?
Health and Care Innovation Expo
 
RDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-RiegerRDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-Rieger
Canadian Organization for Rare Disorders
 
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAPBIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAPNathan White, CPC
 
BIOTECH 2011 NJ/DE/PA Case studies
BIOTECH 2011 NJ/DE/PA Case studiesBIOTECH 2011 NJ/DE/PA Case studies
BIOTECH 2011 NJ/DE/PA Case studiesNathan White, CPC
 
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and                                          ...Principles of Pharmacoeconomics and                                          ...
Principles of Pharmacoeconomics and ...
Aasritha William
 
Apr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgApr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgOffice of Health Economics
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Dr. Tayaba Khan
 
EuroBioForum 2013 - Day 1 | Katherine Payne
 EuroBioForum 2013 - Day 1 | Katherine Payne EuroBioForum 2013 - Day 1 | Katherine Payne
EuroBioForum 2013 - Day 1 | Katherine Payne
EuroBioForum
 
ADAPTIVE PATHWAYS
ADAPTIVE PATHWAYSADAPTIVE PATHWAYS
ADAPTIVE PATHWAYS
Francois MAIGNEN
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APAC
QuintilesIMS Asia Pacific
 
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
HFG Project
 
Balancing needs and resources in medicines delivery
Balancing needs and resources in medicines delivery Balancing needs and resources in medicines delivery
Balancing needs and resources in medicines delivery
Irish Pharmaceutical Healthcare Association (IPHA)
 
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingWebinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Canadian Organization for Rare Disorders
 
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
Nathan White, CPC
 
Day 2: CORD 2021 Fall Conference Slides
Day 2: CORD 2021 Fall Conference SlidesDay 2: CORD 2021 Fall Conference Slides
Day 2: CORD 2021 Fall Conference Slides
Canadian Organization for Rare Disorders
 
Planning SMART Webinar: April 26, 2022
Planning SMART Webinar: April 26, 2022Planning SMART Webinar: April 26, 2022
Planning SMART Webinar: April 26, 2022
Canadian Organization for Rare Disorders
 
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Canadian Cancer Survivor Network
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canadian Organization for Rare Disorders
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
Nathan White, CPC
 
Value based healthcare
Value based healthcareValue based healthcare
Value based healthcare
Asem Shadid
 

Similar to WHAT IF: The entry of new pharmaceuticals was managed and their prices were negotiated based on value for the country as a whole, by using existing health technology assessment capacity? (20)

What can we learn from other countries?
What can we learn from other countries?What can we learn from other countries?
What can we learn from other countries?
 
RDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-RiegerRDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-Rieger
 
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAPBIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
BIOTECH 2011 A POWERFUL PAYER: PRICING & REIMBURSEMENT ROADMAP
 
BIOTECH 2011 NJ/DE/PA Case studies
BIOTECH 2011 NJ/DE/PA Case studiesBIOTECH 2011 NJ/DE/PA Case studies
BIOTECH 2011 NJ/DE/PA Case studies
 
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and                                          ...Principles of Pharmacoeconomics and                                          ...
Principles of Pharmacoeconomics and ...
 
Apr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgApr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mg
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
 
EuroBioForum 2013 - Day 1 | Katherine Payne
 EuroBioForum 2013 - Day 1 | Katherine Payne EuroBioForum 2013 - Day 1 | Katherine Payne
EuroBioForum 2013 - Day 1 | Katherine Payne
 
ADAPTIVE PATHWAYS
ADAPTIVE PATHWAYSADAPTIVE PATHWAYS
ADAPTIVE PATHWAYS
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APAC
 
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
 
Balancing needs and resources in medicines delivery
Balancing needs and resources in medicines delivery Balancing needs and resources in medicines delivery
Balancing needs and resources in medicines delivery
 
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingWebinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug Pricing
 
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Techno...
 
Day 2: CORD 2021 Fall Conference Slides
Day 2: CORD 2021 Fall Conference SlidesDay 2: CORD 2021 Fall Conference Slides
Day 2: CORD 2021 Fall Conference Slides
 
Planning SMART Webinar: April 26, 2022
Planning SMART Webinar: April 26, 2022Planning SMART Webinar: April 26, 2022
Planning SMART Webinar: April 26, 2022
 
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
 
Value based healthcare
Value based healthcareValue based healthcare
Value based healthcare
 

More from CFHI-FCASS

Mythbusters Evaluation
Mythbusters EvaluationMythbusters Evaluation
Mythbusters EvaluationCFHI-FCASS
 
Augmenter la capacité d’une participation significative
Augmenter la capacité d’une participation significativeAugmenter la capacité d’une participation significative
Augmenter la capacité d’une participation significativeCFHI-FCASS
 
Increasing Capacity for Meaningful Engagement
Increasing Capacity for Meaningful EngagementIncreasing Capacity for Meaningful Engagement
Increasing Capacity for Meaningful EngagementCFHI-FCASS
 
L simard cdn-masterclass_presentation-17-05-11_fr
L simard cdn-masterclass_presentation-17-05-11_frL simard cdn-masterclass_presentation-17-05-11_fr
L simard cdn-masterclass_presentation-17-05-11_frCFHI-FCASS
 
L simard cdn-masterclass_presentation-17-05-11
L simard cdn-masterclass_presentation-17-05-11L simard cdn-masterclass_presentation-17-05-11
L simard cdn-masterclass_presentation-17-05-11CFHI-FCASS
 
Restructuration des services de santé et hospitaliers L’expérience de l’Ontario
Restructuration des services de santé et hospitaliers L’expérience de l’Ontario Restructuration des services de santé et hospitaliers L’expérience de l’Ontario
Restructuration des services de santé et hospitaliers L’expérience de l’Ontario
CFHI-FCASS
 
Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999)
Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999) Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999)
Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999)
CFHI-FCASS
 
Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...
Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...
Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...
CFHI-FCASS
 
Current state of NHS reforms
Current state of NHS reformsCurrent state of NHS reforms
Current state of NHS reforms
CFHI-FCASS
 
Restructuring Health and Hospital Services: The Ontario Experience
Restructuring Health and Hospital Services: The Ontario ExperienceRestructuring Health and Hospital Services: The Ontario Experience
Restructuring Health and Hospital Services: The Ontario Experience
CFHI-FCASS
 
Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...
Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...
Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...
CFHI-FCASS
 
Canadian health spending: Managing in a downturn (1990-1999)
Canadian health spending: Managing in a downturn (1990-1999)Canadian health spending: Managing in a downturn (1990-1999)
Canadian health spending: Managing in a downturn (1990-1999)
CFHI-FCASS
 
Knowledge Transfer & Exchange
Knowledge Transfer & ExchangeKnowledge Transfer & Exchange
Knowledge Transfer & ExchangeCFHI-FCASS
 
What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...CFHI-FCASS
 
WHAT IF: Medical saving accounts were established?
WHAT IF: Medical saving accounts were established?WHAT IF: Medical saving accounts were established?
WHAT IF: Medical saving accounts were established?
CFHI-FCASS
 
WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...
WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...
WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...
CFHI-FCASS
 
WHAT IF: The price of new provider fees were coordinated across Canada, suppo...
WHAT IF: The price of new provider fees were coordinated across Canada, suppo...WHAT IF: The price of new provider fees were coordinated across Canada, suppo...
WHAT IF: The price of new provider fees were coordinated across Canada, suppo...
CFHI-FCASS
 
WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...
CFHI-FCASS
 
Diagnosing the fiscal viability of healthcare system Canada
Diagnosing the fiscal viability of healthcare system CanadaDiagnosing the fiscal viability of healthcare system Canada
Diagnosing the fiscal viability of healthcare system CanadaCFHI-FCASS
 
WHAT IF: Social insurance could pay for prescription drugs?
WHAT IF: Social insurance could pay for prescription drugs?WHAT IF: Social insurance could pay for prescription drugs?
WHAT IF: Social insurance could pay for prescription drugs?
CFHI-FCASS
 

More from CFHI-FCASS (20)

Mythbusters Evaluation
Mythbusters EvaluationMythbusters Evaluation
Mythbusters Evaluation
 
Augmenter la capacité d’une participation significative
Augmenter la capacité d’une participation significativeAugmenter la capacité d’une participation significative
Augmenter la capacité d’une participation significative
 
Increasing Capacity for Meaningful Engagement
Increasing Capacity for Meaningful EngagementIncreasing Capacity for Meaningful Engagement
Increasing Capacity for Meaningful Engagement
 
L simard cdn-masterclass_presentation-17-05-11_fr
L simard cdn-masterclass_presentation-17-05-11_frL simard cdn-masterclass_presentation-17-05-11_fr
L simard cdn-masterclass_presentation-17-05-11_fr
 
L simard cdn-masterclass_presentation-17-05-11
L simard cdn-masterclass_presentation-17-05-11L simard cdn-masterclass_presentation-17-05-11
L simard cdn-masterclass_presentation-17-05-11
 
Restructuration des services de santé et hospitaliers L’expérience de l’Ontario
Restructuration des services de santé et hospitaliers L’expérience de l’Ontario Restructuration des services de santé et hospitaliers L’expérience de l’Ontario
Restructuration des services de santé et hospitaliers L’expérience de l’Ontario
 
Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999)
Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999) Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999)
Les dépenses en Santé au Canada : La gestion pendant une récession (1990-1999)
 
Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...
Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...
Réforme des services de Santé en Saskatchewan dans les années 1990 : Leçons d...
 
Current state of NHS reforms
Current state of NHS reformsCurrent state of NHS reforms
Current state of NHS reforms
 
Restructuring Health and Hospital Services: The Ontario Experience
Restructuring Health and Hospital Services: The Ontario ExperienceRestructuring Health and Hospital Services: The Ontario Experience
Restructuring Health and Hospital Services: The Ontario Experience
 
Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...
Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...
Healthcare reform in Saskatchewan in the 1990s: Lessons from the Minister of ...
 
Canadian health spending: Managing in a downturn (1990-1999)
Canadian health spending: Managing in a downturn (1990-1999)Canadian health spending: Managing in a downturn (1990-1999)
Canadian health spending: Managing in a downturn (1990-1999)
 
Knowledge Transfer & Exchange
Knowledge Transfer & ExchangeKnowledge Transfer & Exchange
Knowledge Transfer & Exchange
 
What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...
 
WHAT IF: Medical saving accounts were established?
WHAT IF: Medical saving accounts were established?WHAT IF: Medical saving accounts were established?
WHAT IF: Medical saving accounts were established?
 
WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...
WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...
WHAT IF: Group-based profit-sharing strategies aligned physician incentives w...
 
WHAT IF: The price of new provider fees were coordinated across Canada, suppo...
WHAT IF: The price of new provider fees were coordinated across Canada, suppo...WHAT IF: The price of new provider fees were coordinated across Canada, suppo...
WHAT IF: The price of new provider fees were coordinated across Canada, suppo...
 
WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...
 
Diagnosing the fiscal viability of healthcare system Canada
Diagnosing the fiscal viability of healthcare system CanadaDiagnosing the fiscal viability of healthcare system Canada
Diagnosing the fiscal viability of healthcare system Canada
 
WHAT IF: Social insurance could pay for prescription drugs?
WHAT IF: Social insurance could pay for prescription drugs?WHAT IF: Social insurance could pay for prescription drugs?
WHAT IF: Social insurance could pay for prescription drugs?
 

Recently uploaded

Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
SwastikAyurveda
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
Suraj Goswami
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
SwastikAyurveda
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 

Recently uploaded (20)

Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 

WHAT IF: The entry of new pharmaceuticals was managed and their prices were negotiated based on value for the country as a whole, by using existing health technology assessment capacity?

  • 1. Reimbursement were prices are negotiated based on value for the country as a whole, by using existing health technology assessment : Case Study using Blood Glucose Test Strips Chris Cameron, Health Economist, Canadian Agency for Drugs and Technologies in Health CHSRF iHEA Pre-Conference Symposium, July 11, 2011
  • 2.
  • 3.
  • 4.
  • 5. Example – Blood Glucose Test Strips (c) VBP of test strips at cost-effectiveness threshold of marginal sub-group (a) (b) Current pricing of test strips in Canada (dashed line) a) Diminishing marginal utility of SMBG HTA-based price reduction from $0.76 to $0.30 using would save drug plans >$150 million annually and not compromise the health of Canadians
  • 6.
  • 7.
  • 8.

Editor's Notes

  1. Private, not-for-profit organization founded in 1989 by the F/P/T Deputy Ministers of Health Funded by Health Canada, the provinces and territories Provides evidence-based information about the effectiveness and efficiency of drugs and other health technologies Contributes to the sustainability of our health care system and improved health outcomes for all Canadians
  2. Private, not-for-profit organization founded in 1989 by the F/P/T Deputy Ministers of Health Funded by Health Canada, the provinces and territories Provides evidence-based information about the effectiveness and efficiency of drugs and other health technologies Contributes to the sustainability of our health care system and improved health outcomes for all Canadians
  3. Private, not-for-profit organization founded in 1989 by the F/P/T Deputy Ministers of Health Funded by Health Canada, the provinces and territories Provides evidence-based information about the effectiveness and efficiency of drugs and other health technologies Contributes to the sustainability of our health care system and improved health outcomes for all Canadians
  4. Private, not-for-profit organization founded in 1989 by the F/P/T Deputy Ministers of Health Funded by Health Canada, the provinces and territories Provides evidence-based information about the effectiveness and efficiency of drugs and other health technologies Contributes to the sustainability of our health care system and improved health outcomes for all Canadians
  5. Private, not-for-profit organization founded in 1989 by the F/P/T Deputy Ministers of Health Funded by Health Canada, the provinces and territories Provides evidence-based information about the effectiveness and efficiency of drugs and other health technologies Contributes to the sustainability of our health care system and improved health outcomes for all Canadians
  6. Private, not-for-profit organization founded in 1989 by the F/P/T Deputy Ministers of Health Funded by Health Canada, the provinces and territories Provides evidence-based information about the effectiveness and efficiency of drugs and other health technologies Contributes to the sustainability of our health care system and improved health outcomes for all Canadians
  7. Private, not-for-profit organization founded in 1989 by the F/P/T Deputy Ministers of Health Funded by Health Canada, the provinces and territories Provides evidence-based information about the effectiveness and efficiency of drugs and other health technologies Contributes to the sustainability of our health care system and improved health outcomes for all Canadians